Skip to main content
Immune

Thymosin Alpha-1 vs LL-37

A comprehensive side-by-side comparison of Thymosin Alpha-1 and LL-37 covering mechanisms, benefits, dosing, and safety.

Quick Verdict

Thymosin Alpha-1 enhances adaptive immunity through T-cell maturation and modulation, while LL-37 is a cathelicidin antimicrobial peptide that provides innate immune defense. They address different arms of the immune system.

Thymosin Alpha-1 modulates adaptive immunity (T-cells) LL-37 provides innate antimicrobial defense Thymosin Alpha-1 is approved in some countries LL-37 has direct antimicrobial and anti-biofilm activity

Thymosin Alpha-1

Immune

Thymosin Alpha-1 is a peptide naturally produced by the thymus gland. It plays a crucial role in immune system regulation and has been approved in many countries for treatment of hepatitis B and C, and as an adjunct to cancer therapy.

View Full Profile

LL-37

Immune

LL-37 is the only cathelicidin-derived antimicrobial peptide found in humans. It is a 37-amino-acid peptide cleaved from the C-terminal end of the human cathelicidin protein hCAP18. LL-37 plays a central role in innate immune defense against bacterial, viral, and fungal infections.

View Full Profile

At a Glance

Property
Thymosin Alpha-1
LL-37
Category
Immune
Immune
Molecular Weight
3108 g/mol
4493.33 g/mol
Administration
Subcutaneous injection
Subcutaneous injection or topical application
Typical Dose
1.6 mg
50-100 mcg
Frequency
2 times weekly
As needed or 2-3 times weekly
Duration
6-12 months for chronic conditions
Variable based on research protocol
Purity
99%+
99%+

Mechanism of Action

Thymosin Alpha-1

Thymosin Alpha-1 enhances T-cell function, promotes T-cell maturation, and modulates cytokine production. It activates dendritic cells, increases natural killer cell activity, and helps restore immune balance in immunocompromised states.

LL-37

LL-37 disrupts microbial membranes through electrostatic interactions with negatively charged lipid bilayers. Beyond direct antimicrobial activity, it modulates the immune response by promoting chemotaxis of immune cells, stimulating angiogenesis, enhancing wound healing, and modulating inflammatory cytokine production. It can also neutralize bacterial endotoxins (LPS).

Potential Benefits

Thymosin Alpha-1

  • + Enhanced immune function
  • + Improved T-cell activity
  • + Vaccine adjuvant effects
  • + Antiviral properties
  • + Cancer support

LL-37

  • + Broad-spectrum antimicrobial activity
  • + Enhanced innate immune response
  • + Accelerated wound healing
  • + Biofilm disruption capability
  • + Immune modulation and LPS neutralization

Side Effects

Thymosin Alpha-1

  • ! Injection site reactions
  • ! Transient fever (rare)
  • ! Generally very well tolerated

LL-37

  • ! Injection site irritation
  • ! Local inflammatory response at high doses
  • ! Limited human safety data for systemic use
  • ! Potential mast cell activation at high concentrations

Research Areas

Thymosin Alpha-1

Hepatitis B and C
Cancer immunotherapy
Vaccine enhancement
Immunodeficiency
Sepsis

LL-37

Antimicrobial defense and innate immunity
Wound healing and tissue repair
Biofilm disruption
Anti-inflammatory modulation
Cancer immunotherapy adjuncts

Frequently Asked Questions

Is Thymosin Alpha-1 or LL-37 better for immunity?

They serve different immune functions. Thymosin Alpha-1 enhances the adaptive immune system by promoting T-cell maturation and function. LL-37 is a natural antimicrobial peptide that directly kills pathogens and modulates innate immune responses. They can be complementary.

Can Thymosin Alpha-1 and LL-37 be used together?

Yes, they target different arms of the immune system and can be complementary. Thymosin Alpha-1 addresses adaptive immunity while LL-37 strengthens innate defenses. This combination is used in comprehensive immune support protocols.

Related Comparisons

Explore These Peptides

Learn more about each peptide or find optimized stacking protocols.